Retatrutide Achieves 18.8% Weight Loss in Type 2 Diabetes Phase III Trial | Retatrutide News

Retatrutide led to an 18.8% average weight loss in a Phase III trial for type 2 diabetes patients. This result underscores its potential as a weight man...
Clinical Trials · October 16, 2026